| Literature DB >> 31414242 |
Yan-Ling Liu1, Dun-Wei Wang2, Zhu-Chun Yang3, Rui Ma3, Zhong Li3, Wei Suo3, Zhuang Zhao2, Zhi-Wen Li4.
Abstract
OBJECTIVES: The aim of this analysis was to study the impact of marital status on inflammatory breast cancer (IBC) patients, as the prognostic impact is yet to be studied in detail.Entities:
Keywords: Inflammatory breast cancer; Marital status; SEER; Survival
Mesh:
Year: 2019 PMID: 31414242 PMCID: PMC6797700 DOI: 10.1007/s10549-019-05385-8
Source DB: PubMed Journal: Breast Cancer Res Treat ISSN: 0167-6806 Impact factor: 4.872
Fig. 1Flow chart for screening eligible patients
Baseline demographic and tumor characteristics of patients in SEER database
| Characteristic | Total | Married | Unmarried | |
|---|---|---|---|---|
| Age | 0.002 | |||
| ≤ 56 | 649 (48.36%) | 366 (52.44%) | 283 (43.94%) | |
| >56 | 693 (51.64%) | 332 (47.56%) | 361 (56.06%) | |
| Race | < 0.001 | |||
| White | 1042 (77.65%) | 581 (83.24%) | 461 (71.58%) | |
| Black | 228 (16.99%) | 78 (11.17%) | 150 (23.29%) | |
| Other* | 72 (5.37%) | 39 (5.59%) | 33 (5.12%) | |
| Grade | 0.160 | |||
| Grade I/II | 262 (19.52%) | 141 (20.20%) | 121 (18.79%) | |
| Grade III/IV | 773 (57.60%) | 412 (59.03%) | 361 (56.06%) | |
| Unknown | 307 (22.88%) | 145 (20.77%) | 162 (25.16%) | |
| AJCC stage | < 0.001 | |||
| IIIA | 706 (52.61%) | 385 (55.16%) | 321 (49.84%) | |
| IIIB | 225 (16.77%) | 130 (18.62%) | 95 (14.75%) | |
| IV | 411 (30.63%) | 183 (26.22%) | 228 (35.40%) | |
| HoR | 0.033 | |||
| Positive | 605 (45.08%) | 337 (48.28%) | 268 (41.61%) | |
| Negative | 603 (44.93%) | 300 (42.98%) | 303 (47.05%) | |
| Unknown | 134 (9.99%) | 61 (8.74%) | 73 (11.34%) | |
| HER-2 | 0.967 | |||
| Positive | 40 (2.98%) | 20 (2.87%) | 20 (3.11%) | |
| Negative | 69 (5.14%) | 36 (5.16%) | 33 (5.12%) | |
| Unknown | 1233 (91.88%) | 642 (91.98%) | 591 (91.77%) | |
| Surgery | < 0.001 | |||
| No surgery | 378 (28.17%) | 150 (21.49%) | 228 (35.40%) | |
| Partial mastectomy | 62 (4.62%) | 25 (3.58%) | 37 (5.75%) | |
| Simple mastectomy | 127 (9.46%) | 74 (10.60%) | 53 (8.23%) | |
| Radical mastectomy | 775 (57.75%) | 449 (64.33%) | 326 (50.62%) | |
| Chemotherapy | < 0.001 | |||
| No/unknown | 193 (14.38%) | 65 (9.31%) | 128 (19.88%) | |
| Yes | 1149 (85.62%) | 633 (90.69%) | 516 (80.12%) | |
| Radiotherapy | < 0.001 | |||
| No/unknown | 683 (50.89%) | 325 (46.56%) | 358 (55.59%) | |
| Yes | 659 (49.11%) | 373 (53.44%) | 286 (44.41%) |
HoR hormone receptor
*Other includes American Indian/Alaska native, Asian/Pacific Islander, and unknown
+The comparison results between married and unmarried group
Fig. 2Kaplan–Meier survival curves of cancer-specific survival (a) and overall survival (b) in different marital status
Univariate and multivariate survival analysis of CSS in inflammatory breast cancer patients
| Characteristic | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| Log-rank χ2 | HR | 95% CI | |||
| Marital status | 24.239 | < 0.001 | |||
| Married | Reference | ||||
| Unmarried | 1.188 | 1.033–1.367 | 0.016 | ||
| Age | 2.685 | 0.101 | NI | ||
| ≤ 56 | |||||
| >56 | |||||
| Race | 47.365 | < 0.001 | < 0.001 | ||
| White | Reference | ||||
| Black | 1.663 | 1.398–1.979 | < 0.001 | ||
| Other* | 0.781 | 0.551–1.106 | 0.164 | ||
| Grade | 14.508 | 0.001 | 0.041 | ||
| Grade I/II | Reference | ||||
| Grade III/IV | 1.138 | 0.937–1.381 | 0.191 | ||
| Unknown | 0.914 | 0.729–1.147 | 0.437 | ||
| AJCC stage | 280.068 | < 0.001 | < 0.001 | ||
| IIIA | Reference | ||||
| IIIB | 1.479 | 1.209–1.810 | < 0.001 | ||
| IV | 2.624 | 2.212–3.113 | < 0.001 | ||
| HOR | 68.344 | < 0.001 | < 0.001 | ||
| Positive | Reference | ||||
| Negative | 1.809 | 1.550–2.111 | < 0.001 | ||
| Unknown | 2.185 | 1.728–2.763 | < 0.001 | ||
| HER-2 | 7.187 | 0.028 | 0.006 | ||
| Positive | Reference | ||||
| Negative | 2.208 | 1.114–4.373 | 0.023 | ||
| Unknown | 2.588 | 1.420–4.715 | 0.002 | ||
| Surgery | 318.410 | < 0.001 | |||
| No surgery | Reference | ||||
| Partial mastectomy | 0.493 | 0.350–0.695 | < 0.001 | ||
| Simple mastectomy | 0.495 | 0.375–0.653 | < 0.001 | ||
| Radical mastectomy | 0.484 | 0.401–0.585 | < 0.001 | ||
| Chemotherapy | 64.214 | < 0.001 | |||
| No/unknown | Reference | ||||
| Yes | 0.563 | 0.462–0.687 | < 0.001 | ||
| Radiotherapy | 47.991 | < 0.001 | |||
| No/unknown | Reference | ||||
| Yes | 0.890 | 0.765–1.036 | 0.133 | ||
SEER 2004–2010 (n = 1342)
HoR hormone receptor
*Other includes American Indian/Alaska native, Asian/Pacific Islander, and unknown
Univariate and multivariate survival analysis of OS in inflammatory breast cancer patients
| Characteristic | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| Log-rank χ2 | HR | 95% CI | |||
| Marital status | 34.333 | < 0.001 | |||
| Married | Reference | ||||
| Unmarried | 1.245 | 1.090–1.421 | 0.001 | ||
| Age | 12.079 | 0.001 | |||
| ≤ 56 | Reference | ||||
| >56 | 1.061 | 0.926–1.215 | 0.395 | ||
| Race | 50.956 | < 0.001 | < 0.001 | ||
| White | Reference | ||||
| Black | 1.709 | 1.448–2.017 | < 0.001 | ||
| Other* | 0.857 | 0.624–1.178 | 0.341 | ||
| Grade | 10.623 | 0.005 | 0.055 | ||
| Grade I/II | Reference | ||||
| Grade III/IV | 1.089 | 0.911–1.302 | 0.348 | ||
| Unknown | 0.888 | 0.719–1.096 | 0.267 | ||
| AJCC stage | 267.703 | < 0.001 | < 0.001 | ||
| IIIA | Reference | ||||
| IIIB | 1.448 | 1.200–1.748 | < 0.001 | ||
| IV | 2.399 | 2.040–2.820 | < 0.001 | ||
| HOR | 54.232 | < 0.001 | < 0.001 | ||
| Positive | Reference | ||||
| Negative | 1.656 | 1.433–1.914 | < 0.001 | ||
| Unknown | 1.981 | 1.585–2.476 | < 0.001 | ||
| HER-2 | 6.871 | 0.032 | 0.008 | ||
| Positive | Reference | ||||
| Negative | 1.920 | 1.019–3.619 | 0.044 | ||
| Unknown | 2.291 | 1.319–3.981 | 0.003 | ||
| Surgery | 29.854 | < 0.001 | |||
| No surgery | Reference | ||||
| Partial mastectomy | 0.472 | 0.339–0.657 | < 0.001 | ||
| Simple mastectomy | 0.508 | 0.391–0.661 | < 0.001 | ||
| Radical mastectomy | 0.505 | 0.422–0.604 | < 0.001 | ||
| Chemotherapy | 114.104 | < 0.001 | |||
| No/unknown | Reference | ||||
| Yes | 0.499 | 0.415–0.600 | < 0.001 | ||
| Radiotherapy | 59.602 | < 0.001 | |||
| No/unknown | Reference | ||||
| Yes | 0.864 | 0.748–0.996 | 0.045 | ||
SEER 2004–2010 (n = 1342)
HoR hormone receptor
*Other includes American Indian/Alaska native, Asian/Pacific Islander, and unknown
Fig. 3Kaplan–Meier survival curves of cancer-specific survival in different AJCC stage subgroup IBC patients according to marital status
Fig. 4Kaplan–Meier survival curves of overall survival in different AJCC stage subgroup IBC patients according to marital status